Clinical Trial

Study in Advanced Solid Tumor Patients

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The study will be conducted in 2 phases: Phase 1: Dose-escalation and Dose Level Expansion, Phase 1 will determine the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE). Phase 2: Tumor-Specific Expansions with Dose Optimization, Phase 2 will further evaluate CLIO-8221 in tumor-specific expansion cohorts to optimize dosing and assess preliminary efficacy.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-12-22; most recent amendment 2026-04-29.
Status change: Not Yet Recruiting → Recruiting 2026-03-12
Trial Details
NCT Number NCT07300943
Lead Sponsor Callio Therapeutics
Conditions Advanced Solid Tumor
Enrollment 306 participants
Start Date 2026-03-19
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-07-17 (estimated)
Updated on ClinicalTrials.gov 2026-05-01